Knudson A G
Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA USA.
J Cancer Res Clin Oncol. 1996;122(3):135-40. doi: 10.1007/BF01366952.
According to a "two-hit" model, dominantly inherited predisposition to cancer entails a germline mutation, while tumorigenesis requires a second, somatic, mutation. Non-hereditary cancer of the same type requires the same two hits, but both are somatic. The original tumor used in this model, retinoblastoma, involves mutation or loss of both are somatic. The original tumor used in this model, retinoblastoma, involves mutation or loss of both copies of the RB1 tumor-suppressor gene in both hereditary and non-hereditary forms. In fact, most dominantly inherited cancers show this relationship. New dominantly inherited cancers show this relationship. New questions have arisen, however. When a tumor-suppressor gene is ubiquitously expressed, why is there any specificity of tumor predilection? In some instances, it is clear that two hits produce only a benign precursor lesion and that other genetic events are necessary. As the number of necessary events increase, the impact of the germline mutation diminishes. The number of events is least for embryonal tumors, and relatively small for certain sarcomas. Stem-cell proliferation evidently plays a key role early in carcinogenesis. In some tissues it is physiological, as in embryonic development and in certain tissues in adolescence. In adult renewal tissues, the sites of the common carcinomas, mutation may be necessary to impair the control of switching between renewal and replicative cell divisions; the APC gene may be the target of such a mutation.
根据“两次打击”模型,癌症的显性遗传易感性需要种系突变,而肿瘤发生则需要第二次体细胞突变。同一类型的非遗传性癌症也需要同样的两次打击,但两者都是体细胞性的。该模型中最初使用的肿瘤——视网膜母细胞瘤,在遗传性和非遗传性形式中都涉及RB1肿瘤抑制基因两个拷贝的突变或缺失。事实上,大多数显性遗传癌症都呈现这种关系。然而,新的问题出现了。当一个肿瘤抑制基因普遍表达时,为什么会有肿瘤偏好的特异性呢?在某些情况下,很明显两次打击只会产生良性前体病变,还需要其他遗传事件。随着所需事件数量的增加,种系突变的影响会减小。胚胎性肿瘤所需的事件数量最少,某些肉瘤所需的事件数量相对较少。干细胞增殖显然在致癌早期起着关键作用。在某些组织中,这是生理性的,如在胚胎发育和青春期的某些组织中。在成体更新组织(常见癌症的发生部位)中,可能需要突变来损害更新和复制性细胞分裂之间转换的控制;APC基因可能是这种突变的靶点。